| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| motesanib | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.52 | discontinued in phase 3 | inhibitor |
| motesanib | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.52 | discontinued in phase 3 | unknown |
| motesanib | tyrosine-protein kinase kit | NA | Successful target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.66 | discontinued in phase 3 | unknown |
| motesanib | tyrosine-protein kinase kit | NA | Successful target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.66 | discontinued in phase 3 | inhibitor |
| click here to return to the previous page | ||||||||